Ti-Mesh Frame Comparison for Alveolar Bone Augmentation
Launched by BOSTON UNIVERSITY · Oct 5, 2023
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Partially edentulous
- • Adult dental patients that require moderate 3-D bone augmentation for dental implant site improvement
- Exclusion Criteria:
- • Poor oral hygiene indices for microbial plaque (PI) and gingival inflammation (GI)
- • Patients who have been on Chemotherapy or Radiation therapy within last 5 years.
- • Patients under active treatment with following medications: Bisphosphonates, Gabapentin, Glucocorticoids, Methotrexate, or Estrogen supplements.
- • Subjects under the direct supervision of the PI
- • Smoking more than 10 cigarettes per day
- • Uncontrolled diabetes or other metabolic disorders
About Boston University
Boston University, a leading research institution located in Boston, Massachusetts, is dedicated to advancing health sciences through innovative clinical trials and research initiatives. With a strong emphasis on interdisciplinary collaboration, the university leverages its extensive network of experts and state-of-the-art facilities to conduct rigorous clinical studies aimed at improving patient outcomes and addressing pressing health challenges. Boston University is committed to ethical research practices, patient safety, and the dissemination of findings to foster greater understanding and advancements in medical care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
Serge Dibart, DMD
Principal Investigator
BU Goldman School of Dental Medicine, Oral Biology/Periodontics
Albert M Price, DMD
Study Director
BU Goldman School of Dental Medicine, Oral Biology/Periodontics
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported